Fed Sparks Profit T...
Health Care: Drugs
Exelixis Inc. (EXEL: NASDAQ)
$4.74 -0.03 | -0.63%
05/24/13 - 04:00 PM ET
Insider Trading
| Historical Data | Current | 1 Mo. Ago | 2 Mo. Ago | 3 Mo. Ago | 4 Mo. Ago | 5 Mo. Ago | 6 Mo. Ago |
|---|---|---|---|---|---|---|---|
| Net Insider Transaction | 0 | 11,068 | 11,068 | 11,068 | 7,770 | 7,770 | 770 |
| Shares Bought | 0 | 17,474 | 17,474 | 17,474 | 12,266 | 12,266 | 12,266 |
| Shares Sold | 0 | 6,406 | 6,406 | 6,406 | 4,496 | 4,496 | 11,496 |
Institutional Trading
| Historical Data | Current | 1 Mo. Ago | 2 Mo. Ago | 3 Mo. Ago | 4 Mo. Ago | 5 Mo. Ago | 6 Mo. Ago |
|---|---|---|---|---|---|---|---|
| Total Shares Held | 168.53M | 169.03M | 168.80M | 171.72M | 175.93M | 174.40M | 173.77M |
| Shares Bought | 17.51M | 19.75M | 19.81M | 20.20M | 59.12M | 64.52M | 66.91M |
| Shares Sold | 6.76M | 6.87M | 6.88M | 7.55M | 7.47M | 7.12M | 6.33M |
Portfolios with EXEL
- Portfolio NameUser Type
- ContributorDrugs Facing FDA Approval i...
- ContributorStocks Under-$10 Setting Up...
- ContributorMost-Active Stocks for the ...
- ContributorStocks Under-$10 Moving Hig...
- Contributor10 Stocks That Could Rise i...
- Contributor10 Biotech Stocks Loved and...
- Contributor10 Biotech Trades for Secon...
- UserMy Portfolio
- ContributorCancer Drug Stocks to Trade...
- Userbarry216 Portfolio 1
Latest EXEL Headlines from TheStreet
- EXEL Crosses Above Key Moving Average Level 05.08.13 | 04:05 pm
- 'Mad Money' Lightning Round: Buy, Buy, Buy Toll Brothers 04.17.13 | 06:04 am
- Exelixis Inc. Stock Downgraded (EXEL) 02.27.13 | 04:02 am
- Arena Pharmaceuticals And 6 More Stocks To Watch 01.07.13 | 07:01 pm
- Shorting Alexza Pharma On FDA's Adasuve Approval 12.19.12 | 07:12 am
- Exelixis Scores FDA Approval For Thyroid Cancer Drug 11.29.12 | 04:11 pm
- 'Mad Money' Lightning Round: Buy Philips 66 and Sprint 11.27.12 | 06:11 am
- Cramer's 'Mad Money' Recap: A Tale of Two Markets 11.26.12 | 07:11 pm
- Exelixis Preps For Thyroid Cancer Drug Approval 11.26.12 | 10:11 am
- Cramer's 'Mad Money' Recap: Good Reasons to Stay in the Market 11.13.12 | 07:11 pm
Press Releases for EXEL
- Exelixis Announces Webcast Of March 4 Presentation At The 33rd Annual Cowen Health Care Conference - Business Wire 02.25.13 | 04:02 pm
- Exelixis Selects Swedish Orphan Biovitrum AB As COMETRIQ™ European Distributor For Medullary Thyroid Cancer - Business Wire 02.21.13 | 04:02 pm
- Exelixis Announces Fourth Quarter And Full Year 2012 Financial Results - Business Wire 02.21.13 | 04:02 pm
- Exelixis Announces February 21st Webcast Of Fourth Quarter And Full Year 2012 Financial Results Conference Call - Business Wire 02.07.13 | 04:02 pm
- Exelixis Announces Webcast Of February 12th Presentation At The 15th Annual BIO CEO & Investor Conference - Business Wire 02.06.13 | 05:02 pm
- Exelixis Announces COMETRIQ™ (cabozantinib) Is Now Available In The U.S. - Business Wire 01.24.13 | 11:01 am
- Exelixis Announces Webcast Of January 9 Presentation At The J.P. Morgan 31st Annual Healthcare Conference - Business Wire 12.13.12 | 04:12 pm
- Exelixis Announces EMA Acceptance Of Marketing Authorization Application For COMETRIQ™ (cabozantinib) - Business Wire 11.29.12 | 04:11 pm
- FDA Approves COMETRIQ™ (Cabozantinib) For Treatment Of Progressive, Metastatic Medullary Thyroid Cancer - Business Wire 11.29.12 | 04:11 pm
- Exelixis Announces Webcasts Of Upcoming Investor Conference Presentations In November - Business Wire 11.05.12 | 04:11 pm
Partner Headlines for EXEL
- Four Biotech Stocks On The Clock - Seeking Alpha 02.19.13 | 09:02 am
- 5 Medical Stock Losers From Last Week With High Short Ratios - Seeking Alpha 12.22.12 | 06:12 am
- Biotech Weekly Recap: Loads Of Bullishness, 2 Giant Rallies, And Selling - Seeking Alpha 12.02.12 | 09:12 am
- Exel Presents Interim Data for Cabozantinib 40 mg Dose Cohort in Metastatic Castration-Resistant Prostate Cancer - Benzinga 09.30.12 | 11:09 am
- After Hours Most Active for Sep 4, 2012 : LYB, HT, SHLD, QQQ, KGC, MTL, CVH, BAC, EXEL, MSFT, FB, FRAN - NASDAQ 09.04.12 | 08:09 pm
- UPDATE: Piper Jaffray Reduces PT to $4.50 on Exelixis on Equity Financing Dilution - Benzinga 08.20.12 | 01:08 pm
- Pre-Market Most Active for Aug 9, 2012 : EXEL, RBN, NOK, BAC, CSCO, ALLY^A, SIRI, AHL, QQQ, WIN, SPH, MNST - NASDAQ 08.09.12 | 12:08 pm
- FDA's Oncologic Drugs Advisory Committee to Review Exelixis New Drug Application for Cabozantinib November 9, 2012 - Benzinga 08.09.12 | 08:08 am
- Social Media Outlook for Monday July 30 (SHAW, BBY, EXEL, VHC) - Benzinga 07.30.12 | 01:07 pm
- Jim Cramer Watchdog: SELL Facebook and 'Buy, Buy, Buy' these 4 HOT Stocks - Wall St. Cheat Sheet 07.18.12 | 12:07 pm
